Tags: Beta-Amyloid

announcements

ADDF Statement on Biogen and Eisai Discontinuing Trials of Aducanumab

Pharmaceuticals company Biogen and its partner Eisai announced that they will cease clinical trials for aducanumab after it was indicated the trials were unlikely to succeed.

announcements

New Generation of Therapeutics Based on Understanding of Aging Biology Show Promise for Alzheimer's

A review by the ADDF published in Neurology® explores novel approaches beyond the common amyloid that could slow or prevent Alzheimer's.

blog

Top Five Highlights from AAIC 2018

The ADDF looks back at the 2018 Alzheimer's Association International Conference.

blog

Does Verubecestat Signal the End of the Amyloid Hypothesis?

Merck announces the end of another anti-amyloid drug trial, calling in to question the amyloid hypothesis and the fate of other anti-amyloid drugs.

blog

What Does the Failure of Solanezumab Mean?

Eli Lilly announced that its Alzheimer's drug solanezumab failed in its last phase 3 clinical trial. Howard Fillit, MD, discusses what this means, and where we go from here.

blog

ADDF-Funded PET Imaging Makes Clinical Trial Success Possible

A treatment has reduced beta-amyloid plaques in the brains of patients with Alzheimer’s disease. 

announcements

Ten New Grants Support Alzheimer's Drug Discovery and Biomarker Development

The ADDF has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression.

blog

5 Highlights from the Largest Alzheimer's Conference

Our neuroscientists share highlights from their favorite sessions at the 2014 Alzheimer’s Association International Conference (AAIC) in Copenhagen, Denmark.

announcements

Medicare Panel's Failure to Recommend Payment for New Alzheimer’s Diagnostic Brain Imaging Scans

Howard Fillit, MD and George Vradenburg of USAgainstAlzheimer's issued a joint statement, responding to MEDCAC's opinion to not support Medicare reimbursement for PET amyloid imaging scans.

announcements

ADDF's Seed Funding Leads to FDA Approval of Amyvid™, First Diagnostic Test for Alzheimer's Disease

The FDA has approved Amyvid™, the first diagnostic test for Alzheimer's disease, for which the ADDF provided critical seed funding.